These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 26907512)

  • 1. Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded?
    Giampieri R; Caporale M; Pietrantonio F; De Braud F; Negri FV; Giuliani F; Pusceddu V; Demurtas L; Restivo A; Fontanella C; Aprile G; Cascinu S; Scartozzi M
    Crit Rev Oncol Hematol; 2016 Apr; 100():99-106. PubMed ID: 26907512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Angiogenesis in Colorectal Carcinoma.
    Lopez A; Harada K; Vasilakopoulou M; Shanbhag N; Ajani JA
    Drugs; 2019 Jan; 79(1):63-74. PubMed ID: 30617958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer: A systematic review and pooled analysis.
    Chebib R; Verlingue L; Cozic N; Faron M; Burtin P; Boige V; Hollebecque A; Malka D
    Semin Oncol; 2017 Apr; 44(2):114-128. PubMed ID: 28923209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New molecular targeting drugs for metastatic colorectal cancer].
    Komatsu Y; Harada K; Fukushima H; Yuki S
    Nihon Rinsho; 2014 Jan; 72(1):120-6. PubMed ID: 24597359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Anti-angiogenic treatments in metastatic colorectal cancer: Does a continuous angiogenic blockade make sense?].
    Jary M; Borg C; Bouché O; Kim S; André T; Bennouna J
    Bull Cancer; 2015 Sep; 102(9):758-71. PubMed ID: 26232849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value and effectiveness of angiogenesis inhibitors for colorectal cancer.
    Venook AP
    Clin Adv Hematol Oncol; 2015 Sep; 13(9):561-3. PubMed ID: 26452184
    [No Abstract]   [Full Text] [Related]  

  • 7. Ziv-aflibercept: a novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer.
    Chung C; Pherwani N
    Am J Health Syst Pharm; 2013 Nov; 70(21):1887-96. PubMed ID: 24128964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Sequential inhibition of angiogenesis in metastatic colorectal cancer: activity and efficacy of aflibercept].
    Martines C; Cordio S; Bordonaro R
    Recenti Prog Med; 2015 May; 106(5):239e-43e. PubMed ID: 25994542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aflibercept: A Review in Metastatic Colorectal Cancer.
    Syed YY; McKeage K
    Drugs; 2015 Aug; 75(12):1435-45. PubMed ID: 26220913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current and advancing treatments for metastatic colorectal cancer.
    Sanz-Garcia E; Grasselli J; Argiles G; Elez ME; Tabernero J
    Expert Opin Biol Ther; 2016; 16(1):93-110. PubMed ID: 26549053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Aflibercept (Zaltrap(®)) approved in metastatic colorectal cancer].
    André T; Chibaudel B
    Bull Cancer; 2013 Oct; 100(10):1023-5. PubMed ID: 24047539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aflibercept, a New Way to Target Angiogenesis in the Second Line Treatment of Metastatic Colorectal Cancer (mCRC).
    Scartozzi M; Vincent L; Chiron M; Cascinu S
    Target Oncol; 2016 Aug; 11(4):489-500. PubMed ID: 27412031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential role of nintedanib in treating colorectal cancer.
    Rossi A; Latiano TP; Parente P; Chiarazzo C; Limosani F; Di Maggio G; Maiello E
    Expert Opin Pharmacother; 2017 Aug; 18(11):1153-1162. PubMed ID: 28649871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and pharmacodynamic evaluation of aflibercept for the treatment of colorectal cancer.
    Sanz-Garcia E; Saurí T; Tabernero J; Macarulla T
    Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):995-1004. PubMed ID: 25988772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding the mechanisms of action of antiangiogenic agents in metastatic colorectal cancer: a clinician's perspective.
    Clarke JM; Hurwitz HI; Rangwala F
    Cancer Treat Rev; 2014 Oct; 40(9):1065-72. PubMed ID: 25047778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of aflibercept in the treatment of metastatic colorectal cancer.
    Macarulla T; Sauri T; Tabernero J
    Expert Opin Biol Ther; 2014 Oct; 14(10):1493-505. PubMed ID: 25152076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted therapy for metastatic colorectal cancer: role of aflibercept.
    Mitchell EP
    Clin Colorectal Cancer; 2013 Jun; 12(2):73-85. PubMed ID: 23102896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complete Response to Aflibercept-FOLFIRI in One Patient With Colorectal Cancer Refractory to Bevacizumab-FOLFOX: A Possible Autocrine Vascular Endothelial Growth Factor Receptor 2-Related Mechanism.
    Kim S; Cayre A; Jary M; Jacquin M; Arbez-Gindre F; Fein F; Lakkis Z; Nguyen T; Borg C
    Clin Colorectal Cancer; 2016 Dec; 15(4):e229-e234. PubMed ID: 27600470
    [No Abstract]   [Full Text] [Related]  

  • 19. Ramucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting--its impact on clinical practice.
    Goel G; Sun W
    J Hematol Oncol; 2015 Jul; 8():92. PubMed ID: 26215324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacokinetics and pharmacodynamics of ramucirumab in the treatment of colorectal cancer.
    Gambardella V; Tarazona N; Cejalvo JM; Roselló S; Cervantes A
    Expert Opin Drug Metab Toxicol; 2016; 12(4):449-56. PubMed ID: 26895445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.